Framingham, Mass., October 25, 2007-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today that its financial results for the third quarter 2007 will be released on Thursday, November 1, 2007 before the Nasdaq market opens. Geoffrey F. Cox, Ph.D., Chairman of the Board, Chief Executive Officer and President, will lead the call on November 1 starting at 10:00 a.m. Eastern Time. You may access the live internet broadcast or the subsequent archived recording, on GTC's website at http://www.gtc-bio.com or as follows:
Live Call - In the United States, dial 1-866-362-4666
Outside the United States, dial 617-597-5313
Reference call ID: when prompted 98102321
Audio Archive - In the United States, dial 888-286-8010
Outside the United States, dial 617-801-6888
Reference call ID: when prompted 19270038
NOTE: a replay of the call will be available one hour following the end of the call and will be accessible until November 8, 2007. The earnings webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.earnings.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).
About GTC Biotherapeutics
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. GTC obtained the first approval anywhere in the world for a transgenically produced protein when ATrynŽ, a recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. GTC's intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 or tom.newberry@gtc-bio.com Feinstein Kean Healthcare for GTC
Francesca Nolan
(617) 577-8110 or francesca.nolan@fkhealth.com
Copyright 2007 GTC Biotherapeutics, All Rights Reserved